Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 4/20 | 0.62 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.62 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.56 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.56 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.56 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL642 | 0.89 | AGTR1 (0.49) | AGTR2AGTR1 | |
| SCHEMBL7312362 | 0.84 | AGTR1 (0.50) | AGTR2AGTR1 | |
| SCHEMBL926 | 0.83 | AGTR1 (0.62) | AGTR2AGTR1ABCC4ABCB11PDE3B | |
| SCHEMBL7310582 | 0.83 | AGTR2 (0.49) | AGTR2AGTR1 | |
| SCHEMBL7299323 | 0.82 | AGTR1 (0.46) | AGTR2AGTR1 | |
| SCHEMBL7310297 | 0.81 | AGTR2 (0.47) | AGTR2AGTR1 | |
| SCHEMBL7308729 | 0.81 | AGTR2 (0.55) | AGTR2AGTR1 | |
| SCHEMBL7306374 | 0.81 | AGTR1 (0.49) | AGTR2AGTR1 | |
| SCHEMBL7303319 | 0.80 | AGTR2 (0.47) | AGTR2AGTR1 | |
| SCHEMBL8793508 | 0.80 | AGTR1 (0.42) | AGTR2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249839-A1 | Process for the Preparation of Losartan Potassium Form I | CADILA PHARMACEUTICALS LTD. (IN) | 2007-10-25 | — | — | US | disclosed |
| EP-1471908-B1 | PROCESS FOR PREPARING LOSARTAN POTASSIUM WITH IMPROVED FLOWABILITY | TEVA PHARMA (IL) | 2007-08-08 | — | — | EP | disclosed |
| US-20060241161-A1 | Process for preparing losartan potassium with improved flowability | LIFSHITZ IGOR | 2006-10-26 | — | — | US | disclosed |
| US-20040171843-A1 | Process for preparing losartan potassium with improved flow ability | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-09-02 | — | — | US | disclosed |
| EP-0733366-B1 | Pharmaceutical compositions comprising angiotensin II receptor blocking imidazoles and diuretics | DU PONT (US) | 1998-04-01 | — | — | EP | disclosed |
| EP-0324377-B1 | Angiotensin II receptor blocking imidazoles and combinations thereof with diuretics and NSaids | DU PONT (US) | 1997-04-16 | — | — | EP | disclosed |
| EP-0733366-A2 | Pharmaceutical compositions comprising angiotensin II receptor blocking imidazoles and diuretics | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-09-25 | — | — | EP | disclosed |
| US-5155118-A | Administering angiotensin inhibitor | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-10-13 | — | — | US | disclosed |
| US-5153197-A | Treatment of hypertension with angiotensin II blocking imidazoles | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-10-06 | — | — | US | disclosed |
| US-5138069-A | Treating hypertension and congestive heart failure | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-08-11 | — | — | US | disclosed |
| US-5128355-A | Hypotensive | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-07-07 | — | — | US | disclosed |
| EP-0324377-A2 | Angiotensin II receptor blocking imidazoles and combinations thereof with diuretics and NSaids | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-07-19 | — | — | EP | disclosed |
| WO-1989006233-A1 | ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLES AND COMBINATIONS THEREOF WITH DIURETICS AND NSAIDS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249839-A1 | Process for the Preparation of Losartan Potassium Form I | AGTR1, REN, AGT | AGTR2 4/4885AGTR1 1/4885ABCC4 2414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.